Together, these results document the development of a clinical grade reagent for TCR-based adoptive immunotherapy of human malignancies, targeting the cancer-testis antigen SSX2 using a codon-optimized TCR derived from a melanoma patient. This evidence concerns the gene SSX2 and melanoma.